Skip to main content

Advertisement

SpringerLink
Log in

Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

A Correction to this article was published on 08 January 2018

This article has been updated

Abstract

Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 08 January 2018

    The fourth author’s name was incorrect in the initial online publication. The original article has been corrected.

References

  1. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93–iii101

    Article  PubMed  Google Scholar 

  2. Palmer JD, Siglin J, Yamoah K, Dan T, Champ CE, Bar-Ad V et al. (2015) Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. J Neurooncol 124:215–221

    Article  CAS  PubMed  Google Scholar 

  3. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085–4091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H et al (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334–340

    Article  CAS  PubMed  Google Scholar 

  6. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543

    Article  CAS  PubMed  Google Scholar 

  7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  CAS  PubMed  Google Scholar 

  8. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729

    Article  CAS  PubMed  Google Scholar 

  9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259

    Article  CAS  PubMed  Google Scholar 

  10. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

    Article  CAS  PubMed  Google Scholar 

  12. Hundsberger T, Reardon DA, Wen PY (2017) Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther 17:507–515

    Article  CAS  PubMed  Google Scholar 

  13. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787

    Article  CAS  PubMed  Google Scholar 

  14. Magnuson W, Ian Robins H, Mohindra P, Howard S (2014) Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab. J Neurooncol 117:133–139

    Article  CAS  PubMed  Google Scholar 

  15. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053

    Article  PubMed  PubMed Central  Google Scholar 

  16. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168–2173

    Article  PubMed  Google Scholar 

  17. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC et al (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107:323–333

    Article  CAS  PubMed  Google Scholar 

  19. Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018–2024

    Article  CAS  PubMed  Google Scholar 

  20. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D (2005) Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol 181:768–773

    Article  PubMed  Google Scholar 

  21. Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neuro-oncol 74:167–171

    Article  CAS  Google Scholar 

  22. Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P et al (2015) Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol 122:559–566

    Article  CAS  PubMed  Google Scholar 

  23. Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD et al (2014) Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neurooncol Pract 1:172–177

    PubMed  PubMed Central  Google Scholar 

  24. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972

    Article  PubMed  Google Scholar 

  25. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519

    Article  CAS  PubMed  Google Scholar 

  26. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy?. Strahlenther Onkol 185:235–240

    Article  PubMed  Google Scholar 

  27. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E et al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159

    Article  CAS  PubMed  Google Scholar 

  28. Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B et al (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185–191

    Article  PubMed  Google Scholar 

  29. Torcuator RG, Thind R, Patel M, Mohan YS, Anderson J, Doyle T et al (2010) The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 97:401–407

    Article  CAS  PubMed  Google Scholar 

  30. Sarmey N, Chao ST, murphy ES, Yu JS, Peereboom D, Stevens G et al (2015) The role of salvage radiation in recurrent glioblastoma after bevacizumab failure. ASCO Annual Meeting, Chicago, IL

Download references

Acknowledgements

E.S.B. received an F30 Ruth Kirschstein MD-PhD Fellowship Award (CA180500).

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

    Wenyin Shi, Maria Werner-Wasik & Voichita Bar Ad

  2. Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA

    Erik S. Blomain

  3. Department of Radiation Oncology, University of Pittsburgh Medical Center, Altoona Cancer Center, Altoona, PA, USA

    Joshua Siglin

  4. Department of Radiation Oncology, Ohio State University, Columbus, OH, USA

    Joshua D. Palmer

  5. Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX, USA

    Tu Dan

  6. Cyberknife Center, Huashan Hospital Pudong, Fudan University, Shanghai, China

    Yang Wang

  7. Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, USA

    Jon Glass, Lyndon Kim, James J. Evans, Kevin Judy, Christopher J. Farrell & David W. Andrews

  8. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

    Deepak Bhamidipati

Authors
  1. Wenyin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erik S. Blomain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joshua Siglin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshua D. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tu Dan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Werner-Wasik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jon Glass
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lyndon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Voichita Bar Ad
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Deepak Bhamidipati
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. James J. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kevin Judy
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Christopher J. Farrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. David W. Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenyin Shi.

Ethics declarations

Conflict of interest

No actual or potential conflicts of interest.

Additional information

The original version of this article has been revised: The fourth author's name has been corrected.

A correction to this article is available online at https://doi.org/10.1007/s11060-018-2744-5.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shi, W., Blomain, E.S., Siglin, J. et al. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. J Neurooncol 137, 171–177 (2018). https://doi.org/10.1007/s11060-017-2709-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2709-0

Keywords

Search

Navigation